Table 1.

Demographic features and clinical characteristics of 680 genetically European male GCT survivors at the time of clinical evaluation

CharacteristicNumber (%)
Total patients680
Age at clinical evaluation (years)
Median (range)38 (18–68)
 <20 y5 (0.7%)
 20–29 y124 (18.2%)
 30–39 y251 (36.9%)
 40–49 y186 (27.4%)
 ≥50 y114 (16.8%)
Self-reported race
 White660 (97.1%)
 Non-white20 (2.9%)
Chemotherapy regimen
Cisplatin, bleomycin, etoposide: totala428 (62.9%)
 ≤2 cycles13 (1.9%)
 3 cycles282 (41.5%)
 4 cycles124 (18.2%)
 ≥5 cycles9 (1.3%)
Cisplatin, etoposide: totalb203 (29.9%)
 ≤3 cycles2 (0.3%)
 4 cycles196 (28.8%)
 ≥5 cycles5 (0.7%)
Other cisplatin-based regimen: totalc49 (7.2%)
 3 cycles6 (0.9%)
 4 cycles39 (5.7%)
 ≥5 cycles4 (0.6%)
Cumulative dose of cisplatin (mg/m2), all patientsd
 <30036 (5.3%)
 300258 (37.9%)
 301–39928 (4.1%)
 400328 (48.2%)
 >40030 (4.4%)
Time from completion of chemotherapy to clinical evaluation, y
 Median (range)4.8 (0.4–29.9)
 <2146 (21.5%)
 2–5250 (36.8%)
 6–9127 (18.7%)
 ≥10156 (22.9%)
 Not available1 (0.1%)
Hypertension and on prescription medicatione
 Yes87 (12.8%)
 Nof593 (87.2%)
Diabetes and on prescription medicationg
 Yes21 (3.1%)
 Noh659 (96.9%)
Hypercholesterolemia and on prescription medicationi
 Yes75 (11.0%)
 Noj605 (89.0%)
Smoking status
 Current smoker51 (7.5%)
 Former smoker234 (34.4%)
 Never smoker395 (58.1%)
Average number of alcoholic drinks in past year
 <2 drinks per day593 (87.2 %)
 ≥2 drinks per day84 (12.4 %)
 Not indicated3 (0.4%)
Self-rating of healthk
 Excellent114 (16.8%)
 Very good286 (42.1%)
 Good249 (36.6%)
 Poor/fairl30 (4.4%)
  • aMedian cumulative cisplatin dose for BEP-treated patients was 300 mg/m2 (range, 200–800): 300 mg/m2 (range, 272–400) among those receiving three cycles, and 400 mg/m2 (range, 344–653) among those receiving four cycles. A total of 317 received the standard doses for each cycle (i.e., bleomycin 30 units i.v. weekly, etoposide 100 mg/m2 i.v. daily × 5 days, cisplatin 20 mg/m2 i.v. daily × 5 days) and 111 received a modified dose for at least one cycle.

  • bMedian cumulative cisplatin dose for EP-treated patients was 400 mg/m2 among patients receiving 4 cycles (range, 400–600), and among all patients (range, 200–600). Of patients receiving EP, 129 received standard dose (etoposide 100 mg/m2 i.v. daily × 5 days, cisplatin 20 mg/m2 i.v. daily × 5 days) and 74 received a modified dose for at least one cycle.

  • cOf 49 patients, 24 received cisplatin, etoposide, ifosfamide regimen (17 standard and seven modified), 14 received combination chemotherapy consisting of cisplatin and ifosfamide; three received cisplatin, bleomycin, etoposide, and ifosfamide, one patient received VelP, one patient received PVB, and one patient received unknown cisplatin-based regimen. For the remaining five patients, other combinations of cisplatin-based chemotherapy were applied.

  • dMedian cumulative dose of cisplatin among all patients was 400 mg/m2 (range, 200–800).

  • eIncludes patients who answered “Yes” to (i) Have you ever been diagnosed with high blood pressure? and “Yes, current” to (ii) Have you ever taken prescription medications for high blood pressure (including current use)?

  • fIncludes five patients for whom status of either hypertension diagnosis or current prescription medication use was not reported.

  • gIncludes patients who answered “yes” to either of the following questions: (i) diabetes requiring insulin or (ii) diabetes requiring tablets or pills.

  • hIncludes 13 patients for whom status of diabetes and current prescription medication use was not reported.

  • iIncludes patients who answered “yes, current” to the following question: Have you ever taken prescription medications for high cholesterol?

  • jIncludes three patients for whom status of hypercholesterolemia and on prescription medication use was not reported.

  • kSelf-rating of health was not indicated by one patient.

  • lOut of 30 patients, 25 assigned fair and five assigned poor to their self-rating of health.